Virbac charts strong sales growth, nabs Big Pharma veteran to oversee quality

France's Virbac S.A. turned in a good second quarter, reporting revenues of €221 million ($245 million), up 19% year-over-year. The growth was largely driven by its companion animal business, most notably Sentinel, the brand of parasiticides that Virbac acquired earlier this year from Eli Lilly ($LLY). Sales in the first half rose 18% to €432.5 million ($469 million). Most of that growth came from outside of the U.S., however, because Virbac's St. Louis manufacturing facility ran into manufacturing issues that interrupted supply. A few days before the earnings announcement, Virbac's U.S. division announced that it hired Steven Buchholz as vice president of quality compliance. Buchholz, whose previous experience includes working at Parexel and Idec Pharmaceuticals, will design and implement strategies for regulatory compliance, the company says. Earnings release | Hiring release

Suggested Articles

Payers are now holding up Spark's $850,000 gene therapy as an example of how innovative drug developers can help payers afford pricey new treatments.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

After two years of implementing an across-the-board efficiency plan, fine-tuning its product portfolio and getting manufacturing up to speed on Apoquel, animal…